Treatment of advanced thyroid cancer: role of molecularly targeted therapies

Lorinda L. Covell, Apar Kishor Ganti

Research output: Contribution to journalReview article

9 Scopus citations

Abstract

Advanced thyroid cancer is not amenable to therapy with conventional cytotoxic chemotherapy. However, newer advances in the understanding of the molecular pathogenesis of different subtypes of thyroid cancer have provided new opportunities for the evaluation of molecularly targeted therapies. This has led to multiple clinical trials using various multi-kinase inhibitors and the subsequent US FDA approval of sorafenib for differentiated thyroid cancer and vandetanib and cabozantinib for medullary thyroid carcinoma. This review provides a summary of the current literature for the treatment of advanced thyroid carcinoma and future directions in this disease.

Original languageEnglish (US)
Pages (from-to)311-324
Number of pages14
JournalTargeted Oncology
Volume10
Issue number3
DOIs
StatePublished - Sep 5 2015

    Fingerprint

Keywords

  • Molecularly targeted therapies
  • Multi-kinase inhibitors
  • Thyroid cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Pharmacology (medical)

Cite this